-
Je něco špatně v tomto záznamu ?
The use of patient-derived xenografts and patient-derived organoids in the search for new therapeutic regimens for pancreatic carcinoma. A review
E. Gayibov, T. Sychra, A. Spálenková, P. Souček, M. Oliverius
Jazyk angličtina Země Francie
Typ dokumentu časopisecké články, přehledy
- MeSH
- individualizovaná medicína * metody MeSH
- lidé MeSH
- myši MeSH
- nádorové mikroprostředí účinky léků MeSH
- nádory slinivky břišní * farmakoterapie patologie genetika MeSH
- organoidy * účinky léků patologie MeSH
- protinádorové látky farmakologie terapeutické užití MeSH
- screeningové testy protinádorových léčiv metody MeSH
- xenogenní modely - testy protinádorové aktivity * metody MeSH
- zvířata MeSH
- Check Tag
- lidé MeSH
- myši MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- přehledy MeSH
Patient-derived organoids (PDOs) and xenografts (PDXs) are powerful tools for personalized medicine in pancreatic cancer (PC) research. This study explores the complementary strengths of PDOs and PDXs in terms of practicality, genetic fidelity, cost, and labor considerations. Among other models like 2D cell cultures, spheroids, cancer-on-chip systems, cell line-derived xenografts (CDX), and genetically engineered mouse models (GEMMs), PDOs and PDXs uniquely balance genetic fidelity and personalized medicine potential, offering distinct advantages over the simplicity of 2D cultures and the advanced, but often resource-intensive, GEMMs and cancer-on-chip systems. PDOs excel in high-throughput drug screening due to their ease of use, lower cost, and shorter experimental timelines. However, they lack a complete tumor microenvironment. Conversely, PDXs offer a more complex microenvironment that closely reflects patient tumors, potentially leading to more clinically relevant results. Despite limitations in size, number of specimens, and engraftment success, PDXs demonstrate significant concordance with patient responses to treatment, highlighting their value in personalized medicine. Both models exhibit significant genetic fidelity, making them suitable for drug sensitivity testing. The choice between PDOs and PDXs depends on the research focus, resource availability, and desired level of microenvironment complexity. PDOs are advantageous for high-throughput screening of a diverse array of potential therapeutic agents due to their relative ease of culture and scalability. PDXs, on the other hand, offer a more physiologically relevant model, allowing for a comprehensive evaluation of drug efficacy and mechanisms of action.
3rd Faculty of Medicine Charles University Prague Czech Republic
Biomedical Center Faculty of Medicine in Pilsen Charles University Pilsen Czech Republic
Centre of Toxicology and Health Safety National Institute of Public Health Prague Czech Republic
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc25010437
- 003
- CZ-PrNML
- 005
- 20250429134853.0
- 007
- ta
- 008
- 250415e20241216fr f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.biopha.2024.117750 $2 doi
- 035 __
- $a (PubMed)39689516
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a fr
- 100 1_
- $a Gayibov, Emin $u 3rd Faculty of Medicine, Charles University, Prague, Czech Republic
- 245 14
- $a The use of patient-derived xenografts and patient-derived organoids in the search for new therapeutic regimens for pancreatic carcinoma. A review / $c E. Gayibov, T. Sychra, A. Spálenková, P. Souček, M. Oliverius
- 520 9_
- $a Patient-derived organoids (PDOs) and xenografts (PDXs) are powerful tools for personalized medicine in pancreatic cancer (PC) research. This study explores the complementary strengths of PDOs and PDXs in terms of practicality, genetic fidelity, cost, and labor considerations. Among other models like 2D cell cultures, spheroids, cancer-on-chip systems, cell line-derived xenografts (CDX), and genetically engineered mouse models (GEMMs), PDOs and PDXs uniquely balance genetic fidelity and personalized medicine potential, offering distinct advantages over the simplicity of 2D cultures and the advanced, but often resource-intensive, GEMMs and cancer-on-chip systems. PDOs excel in high-throughput drug screening due to their ease of use, lower cost, and shorter experimental timelines. However, they lack a complete tumor microenvironment. Conversely, PDXs offer a more complex microenvironment that closely reflects patient tumors, potentially leading to more clinically relevant results. Despite limitations in size, number of specimens, and engraftment success, PDXs demonstrate significant concordance with patient responses to treatment, highlighting their value in personalized medicine. Both models exhibit significant genetic fidelity, making them suitable for drug sensitivity testing. The choice between PDOs and PDXs depends on the research focus, resource availability, and desired level of microenvironment complexity. PDOs are advantageous for high-throughput screening of a diverse array of potential therapeutic agents due to their relative ease of culture and scalability. PDXs, on the other hand, offer a more physiologically relevant model, allowing for a comprehensive evaluation of drug efficacy and mechanisms of action.
- 650 12
- $a nádory slinivky břišní $x farmakoterapie $x patologie $x genetika $7 D010190
- 650 12
- $a organoidy $x účinky léků $x patologie $7 D009940
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a zvířata $7 D000818
- 650 12
- $a individualizovaná medicína $x metody $7 D057285
- 650 12
- $a xenogenní modely - testy protinádorové aktivity $x metody $7 D023041
- 650 _2
- $a protinádorové látky $x farmakologie $x terapeutické užití $7 D000970
- 650 _2
- $a myši $7 D051379
- 650 _2
- $a nádorové mikroprostředí $x účinky léků $7 D059016
- 650 _2
- $a screeningové testy protinádorových léčiv $x metody $7 D004354
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Sychra, Tomáš $u 3rd Faculty of Medicine, Charles University, Prague, Czech Republic; Centre of Toxicology and Health Safety, National Institute of Public Health, Prague, Czech Republic; Department of General Surgery, 3rd Faculty of Medicine, Charles University and University Hospital Královské Vinohrady, Prague, Czech Republic
- 700 1_
- $a Spálenková, Alžběta $u Centre of Toxicology and Health Safety, National Institute of Public Health, Prague, Czech Republic; Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic
- 700 1_
- $a Souček, Pavel $u Centre of Toxicology and Health Safety, National Institute of Public Health, Prague, Czech Republic; Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic. Electronic address: pavel.soucek@szu.cz
- 700 1_
- $a Oliverius, Martin $u 3rd Faculty of Medicine, Charles University, Prague, Czech Republic; Department of General Surgery, 3rd Faculty of Medicine, Charles University and University Hospital Královské Vinohrady, Prague, Czech Republic. Electronic address: martin.oliverius@gmail.com
- 773 0_
- $w MED00005486 $t Biomedicine & pharmacotherapy $x 1950-6007 $g Roč. 182 (20241216), s. 117750
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/39689516 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20250415 $b ABA008
- 991 __
- $a 20250429134849 $b ABA008
- 999 __
- $a ok $b bmc $g 2311659 $s 1247518
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2025 $b 182 $c - $d 117750 $e 20241216 $i 1950-6007 $m Biomedicine & pharmacotherapy $n Biomed Pharmacother $x MED00005486
- LZP __
- $a Pubmed-20250415